Climb Bio, Inc. Files 8-K
Ticker: CLYM · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1768446
| Field | Detail |
|---|---|
| Company | Climb Bio, INC. (CLYM) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceutical
TL;DR
Climb Bio (fka Eliem) filed an 8-K on 10/17/25. No major news, just a routine filing.
AI Summary
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 17, 2025, reporting other events. The company, incorporated in Delaware with its principal executive offices in Wellesley Hills, Massachusetts, operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates a corporate event or update for Climb Bio, Inc., which may be relevant to investors tracking the company's progress and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any immediate financial or operational risks.
Key Numbers
- 001-40708 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-2273741 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Climb Bio, Inc. (company) — Registrant
- Eliem Therapeutics, Inc. (company) — Former company name
- October 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 20 William Street, Suite 145 Wellesley Hills, Massachusetts 02481 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Climb Bio, Inc. in this 8-K filing?
The provided text is a header and does not detail the specific 'Other Events' reported. Further review of the full filing is required.
When did Eliem Therapeutics, Inc. change its name to Climb Bio, Inc.?
The date of the name change from Eliem Therapeutics, Inc. to Climb Bio, Inc. was February 19, 2019.
What is Climb Bio, Inc.'s primary industry classification?
Climb Bio, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Climb Bio, Inc.'s principal executive offices located?
The principal executive offices of Climb Bio, Inc. are located at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.
What is the SEC file number for Climb Bio, Inc.?
The SEC file number for Climb Bio, Inc. is 001-40708.
Filing Stats: 972 words · 4 min read · ~3 pages · Grade level 15.5 · Accepted 2025-10-17 07:11:38
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CLYM The Nasdaq Stock Mar
Filing Documents
- d34212d8k.htm (8-K) — 28KB
- 0001193125-25-241951.txt ( ) — 144KB
- clym-20251017.xsd (EX-101.SCH) — 3KB
- clym-20251017_lab.xml (EX-101.LAB) — 18KB
- clym-20251017_pre.xml (EX-101.PRE) — 11KB
- d34212d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for the Company; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," "will," "working" and similar expressions. Forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.; the Company's ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or preclinical studies; competing successfully with o
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: October 17, 2025 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer